Dr. Jyoti Malhotra, MD, MPH

Dr. Malhotra practices at City of Hope Comprehensive Cancer Center - Duarte in Duarte, California.

Dr. Malhotra's NPI, 1598932170, was assigned on May 13, 2008. Dr. Malhotra graduated from Maulana Azad Medical College in 2005. Dr. Malhotra holds California license C176111.

Dr. Malhotra's primary practice is City of Hope Comprehensive Cancer Center - Duarte, at 1500 Duarte Rd, Duarte, CA 91010 in Los Angeles County. The practice phone is (800) 826-4673.

Dr. Malhotra's primary practice is City of Hope Comprehensive Cancer Center - Duarte in Duarte, California. The medical group on file is City of Hope. Dmand AI also links Dr. Malhotra to 1 more other site, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Malhotra practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Malhotra's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Malhotra is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Malhotra's licenses on file in 5 states: California, New York, New Jersey, District of Columbia and Pennsylvania.

Dmand AI lists breast cancer and lung cancer among the conditions Dr. Malhotra treats.

CMS data shows 590 Medicare services from Dr. Malhotra across 4 procedure codes in 2024, for 113 Medicare patients. Medicare paid $59,341 for them. Every service was in an office.

CMS counts 113 Medicare patients who saw Dr. Malhotra in 2024. The largest group is 65 to 74, with 60 patients. 75% of them have cancer, and 75% have high cholesterol. 16% are also on Medicaid. Their average risk score is 2.70, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Malhotra's median patient age at 69, with 63% women.

In 2024, Dr. Malhotra wrote 591 Medicare Part D claims for 67 patients. 54% of them were for generic drugs. CMS names the drug for 419 of them, across 13 drugs with 11 or more claims each, at $3,438,224 in total drug cost. In 2023, CMS named 263 claims across 10 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 93 out of 100 for Dr. Malhotra for performance year 2024, reported as part of a group. Dr. Malhotra accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Malhotra as offering telehealth.

Dmand AI links 134 papers to Dr. Malhotra, published from 2010 to 2025. 2024 was the busiest year, with 12. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and Antineoplastic Combined Chemotherapy Protocols. Dr. Malhotra has published most often in Transl Lung Cancer Res. Dr. Malhotra's most frequent co-authors are Joseph Aisner, Salma K. Jabbour and Janice M. Mehnert.

Dmand AI links Dr. Malhotra to 12 clinical trials, 5 of them phase 2 studies. 8 are still active or recruiting. Conditions studied include Lung Neoplasms, Thoracic Neoplasms and Carcinoma, Bronchogenic. National Cancer Institute (NCI) sponsors the most, 6. Open Payments lists research payments to Dr. Malhotra that name 1 trial.

CMS Open Payments shows 145 general payments to Dr. Malhotra from 25 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 88% of the total. AstraZeneca Pharmaceuticals LP paid the most, $42,568. It also lists 1 research payment totaling $130 in 2024, naming 1 clinical trial.

Dr. Malhotra graduated from Maulana Azad Medical College in 2005.

Dr. Malhotra is in network with 11 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.